Pharmaceutical manufacturing sites are among the primary contributors of drug contamination that has polluted rivers all over the world, according to a U.K. study. Moreover, it was found that [.]
Phico Therapeutics gains £13.1m grant to advance antibacterial therapy
19th April 2021
Cambridge, UK-based Phico Therapeutics has been awarded a grant of up to £13.2m ($18.2m) to take its lead antibacterial therapy through Phase I clinical trials.
The grant comes from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership seeking to accelerate antibacterial research against the growing threat of drug-resistant bacteria.
The funds will be used to support the advancement of Phico’s lead product – SASPject PT3.9 – through clinical trials, with £3.8m available immediately and a further £9.4m contingent on reaching certain project milestones.
Phico’s SASPject PT3.9 is designed for the intravenous treatment of hospital infections caused by the bacterium